A clinical case of early multifocal atherosclerosis complicated by acute coronary syndrome in a young man with ulcerative colitis

Inflammatory bowel disease  (IBD) is a chronic, relapsing, systemic and immune-mediated conditiondis  that  frequently  involve extraintestinal manifestations. Latest  studies  showed  increased risk of cardiovascular  complications,  which is the  main cause of death  in developed countries, in chronic inflammatory disorders, especially during IBD relapses. IBD patients are at increased risk of conditions  such as early atherosclerosis, ischaemic heart  disease, myocardial infarction, stroke, venous thrombosis, heart failure, аtrial fibrillation. Hypotheses  for the  mechanism  underlying  the  association of IBD and atherosclerotic cardiovascular diseases  include adverse  effects of both the IBD itself (chronic inflammation, еndothelium dysfunction, dyslipidemia, thrombocytosis, gut microbiome  dysfunction) and its treatment. The predominant role in atherogenesis is currently assigned  to disruption of the endothelium. Endothelium plays an important role in physiologic regulation of vascular tone, cell adhesion, migration and resistance to thrombosis. Also, its dysfunction  is associated with increased risk of atherosclerosis development. Early multifocal atherosclerosis is a serious complication  of ulcerative  colitis and can occur in young people  without  traditional cardiovascular  risk factors. Untimely diagnosis,  lack of pathogenetic treatment, correction  of basic anti-inflammatory therapy  and comprehensive consideration of a problem  of high cardiovascular  risk can lead to acute  myocardial infarction  and stroke and disability of a patient  of working age. The authors  present a case  report  of multifocal  atherosclerosis complicated by acute coronary syndrome in a young man with ulcerative  colitis, who required  a radical revision of the therapy.

1. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018;24(4):916–923. https://doi.org/10.1093/ibd/izx089.

2. Lazou A, Ikonomidis I, Bartekova M, Benedek T, Makavos G, Palioura D et al. Chronic inflammatory diseases, myocardial function and cardioprotection. Br J Pharmacol. 2020;177(23):5357–5374. https://doi.org/10.1111/bph.14975.

3. Zanoli L, Inserra G, Castellino P. Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: The inflammatory bowel disease paradox. Trends Cardiovasc Med. 2015;25(8):705–706. https://doi.org/10.1016/j.tcm.2015.04.001.

4. Verdugo-Meza A, Ye J, Dadlani H, Ghosh S, Gibson DL. Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. Nutrients. 2020;12(5):1434. https://doi.org/10.3390/nu12051434.

5. Lishchinskaya AA, Knyazev OV, Kagramanova AV, Dudina GA, Sabelnikova EA, Li IA et al. Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases. Terapevticheskii Arkhiv. 2022;94(2):172–179. (In Russ.) https://doi.org/10.26442/00403660.2022.02.201367.

6. Gala D, Newsome T, Roberson N, Lee SM, Thekkanal M, Shah M et al. Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview. Diseases. 2022;10(4):73. https://doi.org/10.3390/diseases10040073.

7. Faye AS, Lee KE, Dodson J, Chodosh J, Hudesman D, Remzi F et al. Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis. Aliment Pharmacol Ther. 2022;56(7):1157–1167. https://doi.org/10.1111/apt.17162.

8. Qu C, Cao J, Liu K, Tan B, Zhu C, Li K, Qu L. Crohn’s Disease Complicated With Extensive Thrombosis of Limbs and Mesenteric Arteries: A Case Report and Literature Review. Ann Vasc Surg. 2019;58:382.e15–382.e19. https://doi.org/10.1016/j.avsg.2018.12.079.

9. Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS ONE. 2013;8(2):e56944. https://doi.org/10.1371/journal.pone.0056944.

10. Aniwan S, Pardi DS, Tremaine WJ, Loftus EV Jr. Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018;16(10):1607–1615.e1. https://doi.org/10.1016/j.cgh.2018.04.031.

11. Pepe M, Cecere A, D’Alessandro P, Fumarola F, Ciccone MM, Marchese A et al. Massive stent thrombosis during active ulcerative colitis: the tricky balance between manifest hemorrhagic and concealed thrombotic risk. Clin Exp Med. 2018;18(4):481–485. https://doi.org/10.1007/s10238-018-0522-5.

12. Panico C, Condorelli G. Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. Clin Rev Allergy Immunol. 2018;55(3):254–270. https://doi.org/10.1007/s12016-017-8624-5.

13. Choi YJ, Choi EK, Han KD, Park J, Moon I, Lee E et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study. World J Gastroenterol. 2019;25(22):2788–2798. https://doi.org/10.3748/wjg.v25.i22.2788.

14. Zuin M, Zuliani G, Rigatelli G, Favero GD, Roncon L. Atrial fibrillation in patients with inflammatory bowel disease: A systematic review and meta-analysis. Eur J Intern Med. 2020;76:120–122. https://doi.org/10.1016/j.ejim.2020.02.029.

15. Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26(12):1231–1241. https://doi.org/10.3748/wjg.v26.i12.1231.

16. Bigeh A, Sanchez A, Maestas C, Gulati M. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? Trends Cardiovasc Med. 2020;30(8):463–469. https://doi.org/10.1016/j.tcm.2019.10.001.

17. Gravina AG, Dallio M, Masarone M, Rosato V, Aglitti A, Persico M et al. Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. Oxid Med Cell Longev. 2018:2568569. https://doi.org/10.1155/2018/2568569.

18. Dowsett L, Higgins E, Alanazi S, Alshuwayer NA, Leiper FC, Leiper J. ADMA: A Key Player in the Relationship between Vascular Dysfunction and Inflammation in Atherosclerosis. J Clin Med. 2020;9(9):3026. https://doi.org/10.3390/jcm9093026.

19. Babaeva GK, Babaev ZM. Frequency of detection of some markers of endothelial dysfunction in patients with inflammatory bowel diseases. Terapevticheskii Arkhiv. 2018;90(4):12–16. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/32439.

20. Magruk MA, Mosikyan AA, Babenko AYu. Biomarkers associated with atherogenesis: current status and promising areas. Russian Journal of Cardiology. 2019;(12):148–152. (In Russ.) https://doi.org/10.15829/1560-4071-2019-12-148-152.

21. Mironova OI, Isaikina MA, Khasieva SA. Atherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskii Arkhiv. 2021;93(12):1533–1538. (In Russ.) https://doi.org/10.26442/00403660.2021.12.201225.

22. Grinevich VB, Radchenko VG. Gut microbiota and metabolic syndrome. Experimental and Clinical Gastroenterology. 2020;183(11):11–19. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-183-11-11-19.

23. Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z et al. Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases. Biomolecules. 2019;9(12):780. https://doi.org/10.3390/biom9120780.

24. Mitchell NE, Harrison N, Junga Z, Singla M. Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(11):2322–2326. https://doi.org/10.1093/ibd/izy157.

25. Grillo TG, Silveira CFDSMP, Quaglio AEV, Dutra RM, Baima JP, Bazan SGZ, Sassaki LY. Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature. World J Cardiol. 2023;15(5):217–228. https://doi.org/10.4330/wjc.v15.i5.217.

26. Konstantinou CS, Korantzopoulos P, Fousekis FS, Katsanos KH. Inflammatory bowel disease and atrial fibrillation: a contemporary overview. Eur J Gastroenterol Hepatol. 2023;35(7):695–701. https://doi.org/10.1097/MEG.0000000000002562.

27. Gawałko M, Balsam P, Lodziński P, Grabowski M, Krzowski B, Opolski G, Kosiuk J. Cardiac Arrhythmias in Autoimmune Diseases. Circ J. 2020;84(5):685–694. https://doi.org/10.1253/circj.CJ-19-0705.

28. Mubasher M, Syed T, Hanafi A, Yu Z, Yusuf I, Abdullah AS et al. An Investigation into the Association Between Inflammatory Bowel Disease and Cardiac Arrhythmias: An Examination of the United States National Inpatient Sample Database. Clin Med Insights Cardiol. 2020;14:1179546820955179. https://doi.org/10.1177/1179546820955179.

29. Cheng CY, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review. Autoimmun Rev. 2022;21(4):103037. https://doi.org/10.1016/j.autrev.2022.103037.

30. Giordani AS, Candelora A, Fiacca M, Cheng C, Barberio B, Baritussio A et al. Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review. Int J Cardiol. 2023;376:165–171. https://doi.org/10.1016/j.ijcard.2023.01.071.

31. Patel RS, Rohit Reddy S, Llukmani A, Hashim A, Haddad DR, Patel DS et al. Cardiovascular Manifestations in Inflammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis. Cureus. 2021;13(3):e14010. https://doi.org/10.7759/cureus.14010.

32. Taha ME, Abdalla A, Al-Khafaji J, Malik S. Mesalamine-Induced Myopericarditis: A Case Report and Literature Review. Cardiol Res. 2019;10(1):59–62. https://doi.org/10.14740/cr820.

33. Shah-Khan SM, Shah-Khan SM, Alqahtani F, Kupec JT. Increasing Rates of Infective Endocarditis in Patients with Inflammatory Bowel Disease. Cureus. 2020;12(2):e6919. https://doi.org/10.7759/cureus.6919.

34. Garcia-Pena A, Ibarrola J, Navarro A, Sadaba A, Tiraplegui C, Garaikoetxea M et al. Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease. Int J Mol Sci. 2021;22(5):2310. https://doi.org/10.3390/ijms22052310.

35. De Almeida Martins C, Caon AER, Facanali CBG, Sobrado CW, Nahas SC, Pereira RMR et al. Coexistence of Takayasu’s Arteritis in Patients with Inflammatory Bowel Diseases. Gastroenterol Res Pract. 2021:8831867. https://doi.org/10.1155/2021/8831867.

36. Weissman S, Sinh P, Mehta TI, Thaker RK, Derman A, Heiberger C et al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol. 2020;11(5):104–113. https://doi.org/10.4291/wjgp.v11.i5.104.

37. Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflamm Bowel Dis. 2023;29(4):531–538. https://doi.org/10.1093/ibd/izac100.

38. Colombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J et al. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2023:S1542-3565(23)00499-8. https://doi.org/10.1016/j.cgh.2023.06.014.

39. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565. https://doi.org/10.1056/NEJMoa021993.

40. Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP et al. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn’s Disease: Real World Evidence From the ENEIDA Registry. J Crohns Colitis. 2023;17(1):83–91. https://doi.org/10.1093/ecco-jcc/jjac108.

41. Lambin T, Faye AS, Colombel JF. Inflammatory Bowel Disease Therapy and Venous Thromboembolism. Curr Treat Options Gastroenterol. 2020;18(3):462–475. https://doi.org/10.1007/s11938-020-00304-z.